What did @charitykface actually say?
The creator was responding to someone just starting tirzepatide at 2.5mg who presumably wasn't seeing results yet. Her core message: "2.5 isn't even a therapeutic dose. It's really not. It's not even a real dose." She extended that skepticism to 5mg and said her personal breakthrough came at 7.5mg, where she felt real weight loss kick in. She capped it with a patience message aimed at people early in their journey.
To be fair, she's speaking from personal experience, not prescribing. She's not telling anyone to skip doses or rush their titration. The framing is anecdotal but the underlying question she's addressing is legitimate: why am I not losing weight yet on the starting dose?
Does the science back this up?
Partially, yes. The 2.5mg dose of tirzepatide is explicitly a titration dose, not a maintenance dose, and the clinical trial data supports the idea that higher doses produce greater weight loss. But calling it "not a real dose" oversimplifies the pharmacology in ways that could cause real harm.
The SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) tested tirzepatide at 5mg, 10mg, and 15mg in adults with obesity. All three doses produced significant weight loss compared to placebo, with 15mg showing the greatest effect. The 2.5mg starting dose was not independently evaluated for efficacy in that trial because it was never intended as a maintenance dose. Eli Lilly designed it as a four-week on-ramp to reduce GI side effects during titration. So she's right that 2.5mg isn't where the therapeutic action lives, but "not a real dose" is a sloppy way to say that. It's a necessary step, not a throwaway one.
Her personal sweet spot at 7.5mg is plausible. Dose-response relationships in GLP-1 and GIP agonists are well-documented. Some patients find their effective dose before hitting the maximum.
What did they get wrong (or right)?
She got the general direction right: lower titration doses are not expected to produce the same weight loss as maintenance doses, and patience during the early phase is genuinely good advice. Clinical guidelines support slow titration precisely because rushing it increases the likelihood of side effects that cause people to quit entirely.
What she got wrong is the language. "Not a real dose" and "not even a therapeutic dose" are phrases that could push people to pressure their prescribers for faster dose escalation, which isn't clinically appropriate for everyone. Some patients with certain health profiles do better staying at lower doses longer. The SURMOUNT-3 trial (Wadden et al., 2023, Nature Medicine) showed that lifestyle intervention layered on top of tirzepatide amplifies outcomes regardless of dose, which is something she didn't mention at all.
She also presented her 7.5mg experience as though it's a milestone everyone should expect, which isn't supported by the data. Some people respond meaningfully at 5mg. Others need 10mg or 15mg. Individual variability in GLP-1 receptor sensitivity is real.
What should you actually know?
If you're at 2.5mg and frustrated, the creator's patience message is actually the most useful thing she said. But here's the more complete picture:
- Tirzepatide's 2.5mg starting dose is a GI tolerance ramp. It was never studied as a standalone weight-loss dose in major trials.
- The SURMOUNT-1 data shows dose-dependent weight loss, meaning higher approved doses produced greater average weight loss, but individual response varies significantly.
- Your "real dose" is not necessarily 7.5mg. It's the dose that balances efficacy and tolerability for your specific physiology, determined with your prescriber over time.
- Rushing titration to chase someone else's results is how people end up with severe nausea, vomiting, or stopping the medication altogether.
- Weight loss on GLP-1 and GIP agonists is not linear. Plateaus happen at every dose level and are not automatically a sign you need to escalate.
Talk to your clinical provider before drawing conclusions from someone else's dose timeline, even a well-meaning one.
Is the patience advice actually medically sound?
Yes, and it's probably the most underrated thing she said. The dropout problem in GLP-1 medication adherence is real and well-documented. Patients who stop early, often because they don't see immediate results, miss the compounding benefits of longer-term use. Wilding et al. (2022, Diabetes, Obesity and Metabolism) demonstrated that weight regain after stopping semaglutide was substantial, reinforcing that these medications require long-term commitment. The same principle applies to tirzepatide. Starting slow, staying consistent, and not measuring your progress against someone else's milestone is genuinely good advice, even if the framing around "real doses" was imprecise.